Internal challenges at the FDA are jeopardizing biotech stocks and investor confidence. Key companies like Amgen, Gilead, and Regeneron face delays that could impact their futures.
Explore the fierce competition in the obesity drug market as Pfizer challenges Novo Nordisk's dominance. Key insights on market dynamics, drug development, and investment potential.
Explore Amgen Inc.'s Q3 2025 financial results, showcasing revenue growth of $9.557B and net income of $3.216B, while navigating ongoing litigation and tax disputes.
Discover Amgen Inc.'s latest 8-K filing detailing its 2.000% Senior Notes due 2026 and stock updates. Stay informed on significant corporate developments and compliance.
Explore Novo Nordisk's rebound in the weight-loss sector amid competition from Eli Lilly, Pfizer, and others. Key insights for investors in the evolving landscape of obesity treatments.
Explore the impact of Eli Lilly's weight-loss pill on the stock market. Analyze risks, competitors, and investment opportunities in the evolving pharmaceutical landscape.
Discover Amgen's impressive Q2 2025 results with $9.179B revenue and $1.432B net income. Learn why it's a buy for investors!
Explore Amgen Inc.'s latest 8-K filing detailing common stock and senior notes. Key insights on financing and corporate strategy included.
Explore Amgen Inc.'s latest 8-K report from May 23, 2025, detailing significant financial activities, including the issuance of 2.00% Senior Notes and stock information.
Explore how the U.S.-China trade tensions impact major companies like CarMax and Harley-Davidson. Analyze market volatility and find strategies for informed investment decisions.
Explore Amgen Inc.'s Q1 2025 financial results showing 9.4% revenue growth, $1.73B net income, and effective debt management. A compelling buy recommendation for investors.
Explore Amgen Inc.'s latest 8-K report detailing common stock, senior notes, and financial strategies as of May 1, 2025. Key insights on debt management and market positioning.